Primary prevention of coronary heart disease: Where do we go from here?

Archives of Internal Medicine

Volumn 161, Issue 7, 2001, Pages 922-924

  Gotto A M , Jr ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLESTYRAMINE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PRAVASTATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EDITORIAL; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; META ANALYSIS; PRIMARY PREVENTION; PRIORITY JOURNAL; SUDDEN DEATH;

EID: 0035832014     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.161.7.922     Document Type: Editorial

References (17)

1. The Lipid Research Clinics Coronary Primary Prevention Trial results, I: Reduction in incidence of coronary heart disease
2. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: Safety of treatment, changes in risk factors, and incidence of coronary heart disease
3. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
4. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
5. Applicability of cholesterol-lowering primary prevention trials to a general population: The Framingham Heart Study
6. The trouble with triglycerides
7. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies
8. Triglyceride concentration and ischemic heart disease: An eight-year follow-up in the Copenhagen Male Study
9. Triglycerides and coronary risk in women and the elderly
10. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: Implications for treatment
11. High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: The Lipid Research Clinics Coronary Primary Prevention Trial
12. The Women's Health Initiative Clinical Trial and Observational Study: History and overview
13. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
14. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) Study
15. Fifteen-year mortality in Coronary Drug Project patients: Long-term benefit with niacin
16. n-3 fatty acids and the prevention of coronary atherosclerosis
17. The Lipid Treatment Assessment Project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals